Presented in part at the XLVIII ERA-EDTA Congress held June 23–26, 2011 in Prague, Czech Republic.
Antibody Response After Single H1N1 Influenza Vaccine in Chronic Dialysis Patients
Article first published online: 20 NOV 2012
© 2012 The Authors. Therapeutic Apheresis and Dialysis © 2012 International Society for Apheresis
Therapeutic Apheresis and Dialysis
Volume 17, Issue 1, pages 55–59, February 2013
How to Cite
Azak, A., Huddam, B., Kocak, G., Altas, A. B., Duranay, M. and Korukluoglu, G. (2013), Antibody Response After Single H1N1 Influenza Vaccine in Chronic Dialysis Patients. Therapeutic Apheresis and Dialysis, 17: 55–59. doi: 10.1111/j.1744-9987.2012.01133.x
- Issue published online: 5 FEB 2013
- Article first published online: 20 NOV 2012
- Received June 2012; revised August 2012.
- Antibody response;
- End stage renal disease;
- H1N1 influenza;
- Peritoneal dialysis;
The first influenza pandemic of this century happened through a rapid spread of a novel swine-derived H1N1 influenza virus. Vaccines are produced in order to avoid the infection. Children and other high risk groups are highly recommended for vaccination due to the high probability of contracting the virus. Chronic kidney disease patients were also accepted as a risk group and vaccination of all patients undergoing hemodialysis or peritoneal dialysis was recommended. The results of H1N1 influenza virus vaccine on patients receiving hemodialysis and peritoneal dialysis are analyzed. Antibody titers of both hemodialysis and peritoneal dialysis patients were elevated after vaccination. Peritoneal dialysis patients responded better.